Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to...
Disability
ThinkSono Joins Butterfly Garden to Deploy ThinkSono AI on Butterfly’s Imaging Platform
ThinkSono enters Butterfly Garden, leveraging Butterfly Network's software development kit (SDK) to build and deploy ThinkSono AI that will be...
Philips and World Stroke Organization partner to improve access to high-quality stroke care
A stroke patient rushed into the hospital October 10, 2023 Two-year partnership focused on advocacy, education, and raising awareness of...
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)...
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...
MediOrbisTM Partners with INTERVENT International to Offer Proven Health Risk Management, Longitudinal Care and Medical Weight Loss Services
CLEVELAND, OH / ACCESSWIRE / October 4, 2023 / MediOrbis, a global multi-specialty telehealth company with comprehensive specialty telemedicine services...
Synchrony Symposium 2023 Advances Research and Clinical Care for Neurodevelopmental Disorders, Including Autism
Dr. Mario Capecchi, Nobel Laureate at University of Utah, to Deliver Keynote on Research to Understand Symptoms Prevalent in Individuals...
Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials
Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to...
Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis
SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed...
BioNTX Names Osteal Therapeutics 2023 Rising Star
President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award...
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as...
NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed...
Osteal Therapeutics Closes $23M Series C Financing
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM...
NeurAxis Reports Second Quarter 2023 Financial Results
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
Receives first purchase order from Gensco® PharmaSAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company"...
Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry
Highlights AHI signs a letter of Intent with Unisure.SCOR (SCR.FP) and Unisure to collaborate with AHI.SCOR is one of the...
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...